Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning.

Journal: The European respiratory journal
Published Date:

Abstract

Epidermal growth factor receptor (EGFR) genotyping is critical for treatment guidelines such as the use of tyrosine kinase inhibitors in lung adenocarcinoma. Conventional identification of EGFR genotype requires biopsy and sequence testing which is invasive and may suffer from the difficulty of accessing tissue samples. Here, we propose a deep learning model to predict EGFR mutation status in lung adenocarcinoma using non-invasive computed tomography (CT).We retrospectively collected data from 844 lung adenocarcinoma patients with pre-operative CT images, EGFR mutation and clinical information from two hospitals. An end-to-end deep learning model was proposed to predict the EGFR mutation status by CT scanning.By training in 14 926 CT images, the deep learning model achieved encouraging predictive performance in both the primary cohort (n=603; AUC 0.85, 95% CI 0.83-0.88) and the independent validation cohort (n=241; AUC 0.81, 95% CI 0.79-0.83), which showed significant improvement over previous studies using hand-crafted CT features or clinical characteristics (p<0.001). The deep learning score demonstrated significant differences in EGFR-mutant and EGFR-wild type tumours (p<0.001).Since CT is routinely used in lung cancer diagnosis, the deep learning model provides a non-invasive and easy-to-use method for EGFR mutation status prediction.

Authors

  • Shuo Wang
    College of Tea & Food Science, Anhui Agricultural University, Hefei, China.
  • Jingyun Shi
    Dept of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
  • Zhaoxiang Ye
    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300060, China. Electronic address: yezhaoxiang@163.com.
  • Di Dong
    The Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
  • Dongdong Yu
    CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
  • Mu Zhou
  • Ying Liu
    The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
  • Olivier Gevaert
    Department of Biomedical Data Science, Stanford University, CA, 94305, USA.
  • Kun Wang
    CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
  • Yongbei Zhu
  • Hongyu Zhou
    Institute for AI in Medicine and Faculty of Medicine, Macau University of Science and Technology, Macau, China; National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
  • Zhenyu Liu
    School of Electronic Information, Hangzhou Dianzi University, Hangzhou 310018, China.
  • Jie Tian
    CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.